A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes

Summary

The main objectives of the current study are to establish the safety and clinical proof-of-concept of NC-503 in inadequately controlled patients with Type 2 diabetes and features of metabolic syndrome treated with either metformin, a sulfonylurea agent, or metformin in combination with a sulfonylurea agent.

Timeline

Start

2008-04

Primary completion

2010-01

Completion

2010-05

Drugs

Indications